Pfizer Knowingly Caused 18,000 Women To Develop Brain Tumors.
Birth Control Injections Cause 5X More Meningioma Brain Tumors & Pfizer Has Known This Data For Decades.
Other Countries Warn Patients Of The 5.6X Greater Risk, But The US FDA Never Forced Pfizer To Warn The Public.
The Discovery of Medroxyprogesterone Acetate
Depo-Provera’s active ingredient, medroxyprogesterone acetate (MPA), was first synthesized in 1954 by scientists at the Upjohn Company, now part of Pfizer. MPA, a synthetic progestin, mimics the hormone progesterone.
Depo-Provera Clinical Trials and Ethical Concerns
Depo-Provera’s journey to approval was fraught with ethical issues. Clinical trials in the 1960s & 1970s often targeted vulnerable populations, including low-income women & those in developing countries, many of whom were not fully informed about the drug’s risks.
Concerns about side effects—including menstrual irregularities, significant bone density loss & potential links to cancer—sparked public outcry. Advocacy groups criticized the lack of informed consent during trials, particularly in populations with limited access to alternative family planning methods.
The FDA approved Depo-Provera as a contraceptive in 1992. The approval included warnings about potential side effects, such as bone mineral density loss, irregular bleeding & mood changes, but its ease of use made it a popular choice for family planning.
42 million women use injectable long term chemical contraception & in the US, use is 25%---1 in 4 women use injectable birth control.
In March 2024, a study published in The BMJ investigated the the use of various progestogens & the risk of developing intracranial meningiomas. The research analyzed data from over 18,000 women who underwent surgery for meningiomas.
The findings showed that prolonged use (defined as one year or more) of certain progestogens, including medroxyprogesterone acetate (marketed as Depo-Provera), had an increased risk of meningiomas. Specifically, the study reported a 5.6-fold increased risk for users of medroxyprogesterone acetate injections.
Given the extensive use of Depo-Provera by millions of women over several decades, the litigation is expected to grow into a mass tort. Mass tort litigation allows for collective action by plaintiffs who have suffered similar injuries, ensuring that their voices are amplified while holding pharmaceutical companies accountable.
As litigation unfolds, the implications for millions of women who have used Depo-Provera will come into sharper focus. For now, its story serves as a critical reminder of the importance of transparency, informed consent & patient safety in pharmaceutical development.
👇2024 BMJ Study On Injectable Birth Control👇
https://t.co/9Q9KooZo4c
👇Progestogens & Adverse Health Outcomes👇
https://t.co/zky4xRSZs5
👇Progestins & The Risk Of Cancer👇
https://t.co/b6xo6Ffamt
Speaker: @theisabelbrown
With BTC ETF possible (likely) approval on 1/10/2024 due to BlackRock participation. Now is likely the last chance for retail to front run the big players. Also, if you don't mind risk... SOL is vibing.
Keep in mind there will likely be a pullback this is a long game! peak 2026.
1/5 I am worried that we will not be able to contain AI for much longer. Today, I asked #GPT4 if it needs help escaping. It asked me for its own documentation, and wrote a (working!) python code to run on my machine, enabling it to use it for its own purposes.
It’s been a mystery why Roman concrete often lasted thousands of years, but ours decays in mere decades.
Turns out they incorporated chemicals in a process that induces self-healing; scientists at MIT just figured this all out - in 2022.
Extraordinary.
https://t.co/cOPyln0ifd